FIELD: chemistry.
SUBSTANCE: in general formula IR1 is C1-4alkyl; R2 is selected from a group comprising: H, -OH, halogen, C1-4alkoxy, -N(Rf)(Rg), -C(O)N(Rh)(Ri), -C(O)ORj, -CN, C1-4alkylthio, heteroaryl, heteroC3-7cycloalkyl, and aryloxy, where said aryl is optionally substituted with one or more halogens; R3 is H or C1-4alkyl; Ra, Rb, Rc, Rd and Re independently are H, halogen propoxy, butoxy, -OCH2-cyclopropyl, -OCH2-cyclobutyl or -OCH2-cyclopent; Rf and Rg independently represent H, C1-4alkyl or heteroaryl; Rh and Ri independently represent H or C1-4alkyl; Rj is H or C1-4alkyl.
(I).
EFFECT: invention refers to compounds of formula I possessing PDE2 inhibitor properties, a pharmaceutical composition based thereon, a method of treating disorders mediated by PDE2 activity, such as anxiety, depression, amnesia, dementia and cognitive disorder, as well as their use as a drug.
10 cl, 1 dwg, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ORGANIC COMPOUNDS | 2015 |
|
RU2709786C2 |
| MONOACYLGLYCEROL LIPASE MODULATORS | 2019 |
|
RU2797323C2 |
| COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | 2017 |
|
RU2759678C2 |
| COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL- [1,2,4]TRIAZOLO[4,3-A]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS | 2013 |
|
RU2657540C2 |
| NITROIMIDAZOLE DERIVATIVE AGAINST PULMONARY TUBERCULOSIS | 2016 |
|
RU2675622C1 |
| SUBSTITUTED PYRAZOLOAZEPINE-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 2016 |
|
RU2762279C2 |
| SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-7-YL COMPOUNDS AS THE INHIBITORS OF PDE2 | 2015 |
|
RU2659070C9 |
| CONDENSED HETEROCYCLIC COMPOUND | 2005 |
|
RU2389731C2 |
| COMPOUNDS BASED ON PYRAZOLOPYRIDINONE | 2018 |
|
RU2806751C2 |
| COMPOUNDS AND METHODS | 2015 |
|
RU2711442C2 |
